IO360° Summit - Overview Page

11th Annual:
Reporting on the Latest Advancements and Data in IO

Immuno-Oncology 360° offered an unparalleled opportunity to hear from stakeholders representing both the science and business communities who reported on the latest data impacting IO to fight a wider range of cancers.

IO360° Delivers 3 Key Benefits

1. Access to KOLs and stakeholders in the science and business communities, reporting on cutting-edge research and trends shaping IO technology, investment, and innovation

2. Presentations featuring 100+ talks on the latest innovative research delivered by international leaders from academia, investors, and industry representatives

3. 10+ hours of networking and business development opportunities to connect with 550+ attendees who specialize in cancer immunotherapy

2025 Key Topics

Biomarkers/Assay Development

Business and Investing Aspects

Discovery/Preclinical

Autoimmune Disease & IO

ADCs & IO

IO Combinations

Translational Science

Imaging Advancements

Cell Therapy

Clinical Operations

Clinical Developments

Neoadjuvant/Adjuvant Therapy

New Tech in Transformational Biology

And More

Networking and Business Opportunities

Partnering/One-on-One Meetings:

• Dedicated partnering tables to connect with fellow industry professionals, investors and KOLs
• Partnering tool to schedule partnering meetings
• Meeting times occur throughout all breaks, lunches and receptions
• Set up multiple meetings per day
• Search other attendee profiles
• Send private message to other attendees
• Dedicated partnering help desk

Scheduled Networking:

IO360° networking opportunities take place throughout the entire event including:

• Scheduled morning and afternoon breaks
• Lunches
• Reception
• Access to the Exhibit hall
• Early evening organized historical walks of downtown Brooklyn

2025 Event Features

Who Attends

Companies Attending:

• AbbVie
• Abingworth
• Amgen
• Astellas Pharma
• AstraZeneca
• Avidity Partners
• Bayer Oncology
• BioNTech
• BMS
• Boehringer Ingelheim
• City of Hope

• Daichii-Sankyo
• Fred Hutchinson Cancer Center
• Invus Group
• Janssen
• Kite Pharma
• Memorial Sloan Kettering Cancer Center
• Merck
• Moderna
• Morgan Stanley

• Mount Sinai
• MPM BioImpact
• NCI
• Novartis
• OrbiMed
• RA Capital
• Regeneron
• Stanford University
• Stifel
• Takeda
• And More!

"By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there's quite a lot of folks participating who are not traditionally talking to one another on a daily basis." - Dr Roy Baynes, Eikon Therapeutics